DE602005017475D1 - Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie - Google Patents

Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie

Info

Publication number
DE602005017475D1
DE602005017475D1 DE602005017475T DE602005017475T DE602005017475D1 DE 602005017475 D1 DE602005017475 D1 DE 602005017475D1 DE 602005017475 T DE602005017475 T DE 602005017475T DE 602005017475 T DE602005017475 T DE 602005017475T DE 602005017475 D1 DE602005017475 D1 DE 602005017475D1
Authority
DE
Germany
Prior art keywords
denotes
arg
chelates
conjugates
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005017475T
Other languages
German (de)
English (en)
Inventor
Dagfinn Lovhaug
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
GE Healthcare AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare AS filed Critical GE Healthcare AS
Publication of DE602005017475D1 publication Critical patent/DE602005017475D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602005017475T 2004-03-04 2005-03-03 Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie Expired - Lifetime DE602005017475D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20040953 2004-03-04
PCT/NO2005/000078 WO2005084715A2 (en) 2004-03-04 2005-03-03 Conjugates of angiotensin peptidic analogues and chelating agents for diagnosis and therapy

Publications (1)

Publication Number Publication Date
DE602005017475D1 true DE602005017475D1 (de) 2009-12-17

Family

ID=34918859

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005017475T Expired - Lifetime DE602005017475D1 (de) 2004-03-04 2005-03-03 Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie

Country Status (7)

Country Link
US (1) US7763234B2 (cg-RX-API-DMAC7.html)
EP (1) EP1729823B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007526300A (cg-RX-API-DMAC7.html)
CN (1) CN1925876A (cg-RX-API-DMAC7.html)
AT (1) ATE447417T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005017475D1 (cg-RX-API-DMAC7.html)
WO (1) WO2005084715A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0416062D0 (en) * 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
WO2006036071A2 (en) * 2004-09-29 2006-04-06 Ge Healthcare As Urokinase plasminogen activator receptor targeted contrast agent
AU2005307195A1 (en) * 2004-11-22 2006-05-26 Ge Healthcare As Contrast agents to target extracellular matrix
WO2010089757A2 (en) * 2008-11-07 2010-08-12 Usv Limited An improved process for synthesis of cyclic octapeptide
US9730916B2 (en) * 2014-02-27 2017-08-15 Chang Gung Memorial Hospital, Keelung Nutritional composition and method for improving heart failure
EP3759121A1 (en) 2018-03-01 2021-01-06 Trigemina, Inc. Labeled oxytocin and method of manufacture and use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966896A (en) 1974-09-06 1976-06-29 Mallinckrodt, Inc. Radioimmunoassay for plasma renin activity
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4687659A (en) 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
WO1993012819A1 (en) 1992-01-03 1993-07-08 Rhomed Incorporated Protein- and peptide-metal ion pharmaceutical applications
ATE314097T1 (de) * 1996-10-28 2006-01-15 Amersham Health As Kontrastmittel
CA2269985A1 (en) 1996-10-28 1998-05-07 Aslak Godal Improvements in or relating to diagnostic/therapeutic agents
US6230777B1 (en) 1999-02-04 2001-05-15 Midmac Systems, Inc. Filter forming and joining apparatus
JP5043271B2 (ja) 2000-04-12 2012-10-10 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチドベースの化合物
WO2002020610A2 (en) * 2000-09-07 2002-03-14 Biosynthema Inc. Conformationally constrained labeled peptides for imaging and therapy
GB0116815D0 (en) * 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
CN1622830A (zh) * 2001-07-10 2005-06-01 安盛药业有限公司 肽基化合物
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
US7785566B2 (en) 2003-11-06 2010-08-31 Ge Healthcare, Inc. Pharmaceutical compounds

Also Published As

Publication number Publication date
CN1925876A (zh) 2007-03-07
JP2007526300A (ja) 2007-09-13
WO2005084715A2 (en) 2005-09-15
WO2005084715A3 (en) 2006-06-15
US20070297979A1 (en) 2007-12-27
EP1729823A2 (en) 2006-12-13
ATE447417T1 (de) 2009-11-15
US7763234B2 (en) 2010-07-27
EP1729823B1 (en) 2009-11-04

Similar Documents

Publication Publication Date Title
US11083710B2 (en) PSMA binding ligand-linker conjugates and methods for using
SG149895A1 (en) Contrast agents for myocardial perfusion imaging
DK1105409T3 (da) Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter
IL180896A0 (en) Method of tumour imaging
ATE439868T1 (de) Targetingmittel für molekulare bilderzeugung
ATE368853T1 (de) Zell-selektives abgabe system
WO2002083866A3 (en) Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
MY148086A (en) Antibodies directed against amyloid-beta peptide and methods using same
DE60217090D1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
DK1272507T3 (da) Integrinbindende peptidderivater
EP2253333A3 (en) Contrast Agents for Myocardial Perfusion Imaging
GB0326546D0 (en) Inhibitor imaging agents
NO20072120L (no) Enzyme Inhibitor Imaging Agents
ATE447417T1 (de) Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie
ATE272074T1 (de) An neuropeptide gebundenes rgd (arg-gly-asp)
DE602004027048D1 (de) Verbindungen und methoden für das downregulating der effekte von tgf-beta
EP2340845A3 (en) Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
ATE289612T1 (de) Diagnostische verwendungen von gegen acetylcholinesterase oder deren c-terminale peptide gerichteten antikörpern
DE60219645D1 (de) Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft
ATE425770T1 (de) Kontrastmittel
WO2005044313A3 (en) Conjugates of angiotensin ii and an imaging moiety
ATE554790T1 (de) Verfahren und zusammensetzungen zur diagnose von asthma
DE60033697D1 (de) Radiomarkierte vip-analoge zur diagnose und therapie
ATE360212T1 (de) Verfahren zur diagnose der effektivität der xenotypischen antikörpertherapie
Alfaro-Lopez et al. Peptide-Lisinopril Conjugates: Design, Synthesis and Biological Activities

Legal Events

Date Code Title Description
8364 No opposition during term of opposition